Orthopediatrics (KIDS) Upgraded to Buy at Zacks Investment Research

Orthopediatrics (NASDAQ:KIDS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday. The firm presently has a $46.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 5.92% from the stock’s current price.

According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “

Several other research firms have also weighed in on KIDS. BidaskClub upgraded Orthopediatrics from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. BTIG Research lifted their price target on Orthopediatrics to $44.00 and gave the company a “buy” rating in a research report on Friday, March 8th. Finally, JMP Securities assumed coverage on Orthopediatrics in a research report on Wednesday, February 20th. They set an “outperform” rating and a $44.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Orthopediatrics currently has a consensus rating of “Buy” and a consensus price target of $41.00.

KIDS opened at $43.43 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.77 and a current ratio of 10.54. Orthopediatrics has a 52-week low of $14.00 and a 52-week high of $44.25. The company has a market cap of $597.36 million, a PE ratio of -45.24 and a beta of 0.18.

Orthopediatrics (NASDAQ:KIDS) last posted its earnings results on Wednesday, March 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.19). Orthopediatrics had a negative return on equity of 22.99% and a negative net margin of 20.89%. The firm had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $14.50 million. During the same period in the previous year, the firm earned ($1.41) earnings per share. The business’s revenue was up 24.8% compared to the same quarter last year. As a group, equities analysts anticipate that Orthopediatrics will post -0.41 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in KIDS. We Are One Seven LLC bought a new stake in Orthopediatrics in the fourth quarter worth $39,000. Bank of Montreal Can boosted its holdings in Orthopediatrics by 4,156.3% in the fourth quarter. Bank of Montreal Can now owns 2,043 shares of the company’s stock worth $71,000 after acquiring an additional 1,995 shares in the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in Orthopediatrics in the fourth quarter worth $93,000. MetLife Investment Advisors LLC bought a new stake in Orthopediatrics in the fourth quarter worth $128,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in Orthopediatrics in the fourth quarter worth $168,000. 51.70% of the stock is currently owned by institutional investors and hedge funds.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

See Also: How to invest in a bear market

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.